Kentucky partners update equine Salmonella vaccine

VERSION 2 — FULL ANALYSIS

A long-running Kentucky equine health partnership is back with a new target: Salmonella. Hagyard Equine Medical Institute, the University of Kentucky’s Gluck Equine Research Center, and the Kentucky Thoroughbred Association have announced an updated Salmonella vaccine for horses, adding two new subspecies intended to improve protection against infections that veterinarians say have been rising in recent years. (truenicks.com)

This isn’t the group’s first vaccine collaboration. The partners said they previously worked together roughly 15 years ago to create Salmonella and Clostridium vaccines in response to emerging disease concerns in Central Kentucky’s Thoroughbred population. The new effort builds on that earlier work, but with a more genomics-driven approach shaped by changes in the strains now showing up in the field. (truenicks.com)

The most important scientific signal behind the update appears to be the emergence of Salmonella enterica serotype Saintpaul in Kentucky horses. A 2026 Veterinary Microbiology paper from University of Kentucky-affiliated researchers reported that, between 2018 and 2025, 245 equine Salmonella isolates were identified, with Saintpaul becoming newly prominent in 2025. The paper said 21 Saintpaul cases were detected that year, all from Central Kentucky, and linked mainly to young foals with enterocolitis, bronchopneumonia, omphalitis, and septicemia. The isolates showed low genetic diversity, suggesting a closely related cluster, and carried multiple antimicrobial resistance genes. (scholars.uky.edu)

That aligns with the partnership’s public explanation of why the vaccine was revised. In the announcement, Hagyard’s Dr. Nathan Slovis said veterinarians had observed an increase in horses with Salmonella and began working to improve the existing vaccine. Gluck’s Dr. Yosra Helmy said whole-genome sequencing helped identify the circulating strain and support a targeted vaccine update, framing the project as a rapid translation of genomic surveillance into a practical prevention tool. The announcement also said Hagyard veterinarians, including Slovis and Dr. Luke Fallon, and the Hagyard Laboratory helped lead the vaccine enhancement and efficacy assessment, with financial support from the Kentucky Thoroughbred Association. (truenicks.com)

Independent expert reaction was limited in public sources, but the broader research context supports the concern. Gluck has highlighted infectious disease and immunology as a core research area and has a long track record in equine vaccine development. In its Equine Disease Quarterly, Gluck also noted that Salmonella is one of the most common causes of bacterial enteritis in horses and described ongoing work to accelerate vaccine development against equine infectious disease threats. (ivis.org)

Why it matters: For veterinary professionals, especially those serving breeding farms, foal populations, and referral hospitals, the news matters for two reasons. First, Salmonella in horses is a clinical, operational, and zoonotic problem, with implications for isolation capacity, staff safety, environmental contamination, and client communication. Second, the emergence of a multidrug-resistant Saintpaul cluster suggests prevention may become more important as treatment decisions get harder. An updated vaccine won’t replace testing, infection-control protocols, or antimicrobial stewardship, but it could become a useful added layer in high-risk settings if field performance holds up. (scholars.uky.edu)

There are still important unknowns. The public announcement did not provide product licensing status, commercial availability, label details, challenge-study data, or peer-reviewed efficacy results for the revised formulation. So, for now, this looks like a meaningful regional vaccine-development story with strong scientific rationale, but one that still needs more transparency on outcomes and deployment. That’s especially relevant for veterinarians deciding whether this is best viewed as a research-driven biologic for targeted use or an intervention likely to scale more broadly. (truenicks.com)

What to watch: The next signals to watch are whether peer-reviewed efficacy data emerge, whether the vaccine moves into wider field use in Kentucky, and whether surveillance shows a drop in Saintpaul-linked equine cases or severity over the next foaling cycles. (scholars.uky.edu)